Knight Therapeutics Boosts Revenue Guidance on Strong Q2 Performance
Event summary
- Knight Therapeutics reported a 34% year-over-year revenue increase to $144.2 million in Q2 2026, driven by promoted products and acquisitions.
- Adjusted EBITDA rose 58% to $24.6 million, with gross margin expanding to 49% from 46%.
- The company raised its full-year revenue guidance to $540–$560 million, up from $510–$525 million.
- Knight completed four commercial launches across Latin America and Canada, including Tavalisse® in Mexico and Molapib® in Argentina.
The big picture
Knight Therapeutics' strong Q2 performance reflects its strategic focus on acquiring and commercializing pharmaceutical products in Latin America and Canada. The revenue guidance upgrade underscores confidence in its promoted portfolio, but regulatory challenges and market dynamics will shape its trajectory. With a diversified product pipeline and healthy cash flows, Knight is positioning itself for continued growth despite external pressures.
What we're watching
- Regulatory Hurdles
- Health Canada's Notice of Non-Compliance for Crexont® and the withdrawal of Qelbree® submission could delay product approvals.
- Market Expansion
- The success of recent launches in Latin America will determine Knight's ability to sustain revenue growth.
- Financial Discipline
- Whether the company can maintain its improved gross margins amid rising operating expenses.
Related topics